A Phase 2 Study of Glasdegib for the Treatment of Acute Myeloid Leukemia and Myelodysplastic Syndrome Patients with High Risk of Post-Allogeneic Stem Cell Transplantation Relapse
Abstract
Introduction: Relapse of acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS) after allogeneic stem cell transplantation (ASCT) is the major cause of mortality. One of the main risk factors for this outcome is the persistence of measurable residual disease (MRD) after achieving a remission and prior to ASCT conditioning. Relapse after ASCT occurs due to persistence of the leukemic stem cell (LSCs) population; LSCs have aberrant...
Paper Details
Title
A Phase 2 Study of Glasdegib for the Treatment of Acute Myeloid Leukemia and Myelodysplastic Syndrome Patients with High Risk of Post-Allogeneic Stem Cell Transplantation Relapse
Published Date
Nov 13, 2019
Journal
Volume
134
Issue
Supplement_1
Pages
1311 - 1311
Citation AnalysisPro
You’ll need to upgrade your plan to Pro
Looking to understand the true influence of a researcher’s work across journals & affiliations?
- Scinapse’s Top 10 Citation Journals & Affiliations graph reveals the quality and authenticity of citations received by a paper.
- Discover whether citations have been inflated due to self-citations, or if citations include institutional bias.
Notes
History